Protocol title: Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)
Registry: ClinicalTrials.gov
Registry #: NCT02647086
Link to registry: See Registry
Protocol title: A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis (VOYAGE 1)
Registry: ClinicalTrials.gov
Registry #: NCT02207231
Link to registry: See Registry
Protocol title: Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
Registry: ClinicalTrials.gov
Registry #: NCT02134210
Link to registry: See Registry
Protocol title: Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis (PSOR-003)
Registry: ClinicalTrials.gov
Registry #: NCT00606450
Link to registry: See Registry
Protocol title: A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)
Registry: ClinicalTrials.gov
Registry #: NCT01729754
Link to registry: See Registry
Protocol title: Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis (FIXTURE)
Registry: ClinicalTrials.gov
Registry #: NCT01358578
Link to registry: See Registry
Protocol title: Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year (ERASURE)
Registry: Australian New Zealand Clinical Trials Registry (ANZCTR)
Registry #: NCT01365455
Link to registry: See Registry
Protocol title: Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis (GESTURE)
Registry: ClinicalTrials.gov
Registry #: NCT01806597
Link to registry: See Registry
